[pubmed] Description of 3 patients with myasthenia gravis and COVID-19
Posté : 31 juil. 2020 12:00
J Neurol Sci. 2020 Jul 22;417:117053. doi: 10.1016/j.jns.2020.117053. Online ahead of print.
ABSTRACT
BACKGROUND: The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.
CASE DESCRIPTION: We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.
CONCLUSION: Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
PMID:32731059 | DOI:10.1016/j.jns.2020.117053
Source: https://pubmed.ncbi.nlm.nih.gov/3273105 ... 9&v=2.11.4